Dalfopristin

Summary

Dalfopristin (CHEMBL1200937) is an approved small-molecule antibacterial drug; indicated across 1 condition including osteomyelitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 1 condition
• Chemistry: 690.8 Da · C34H50N4O9S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200937
Name	Dalfopristin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	6323289
ChEBI	CHEBI:4309
Molecular formula	C34H50N4O9S
Molecular weight	690.8
InChIKey	SUYRLXYYZQTJHF-VMBLUXKRSA-N

SMILES: CCN(CC)CCS(=O)(=O)[C@@H]1CCN2[C@H]1C(=O)O[C@@H]([C@@H](/C=C/C(=O)NC/C=C/C(=C/[C@H](CC(=O)CC3=NC(=CO3)C2=O)O)/C)C)C(C)C

IUPAC name: (6R,7S,10R,11R,12E,17E,19E,21S)-6-[2-(diethylamino)ethylsulfonyl]-21-hydroxy-11,19-dimethyl-10-propan-2-yl-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.03,7]octacosa-1(27),12,17,19,25(28)-pentaene-2,8,14,23-tetrone

ChEBI definition: A macrolide that is pristinamycin IIA in which the double bond between positions 26 and 26a of the pyrroline ring has been reduced and position 26R carries a [2-(diethylamino)ethyl]sulfonyl group. It is a semi-synthetic streptogramin antibiotic and often used as a mixture with quinupristin for the treatment of vancomycin-resistant Enterococcus faecium.

Pharmacological roles (ChEBI): antibacterial drug, protein synthesis inhibitor.

Also known as: Dalfopristin, Dalfopristin component of synercid, Dalfopristina, Dalfopristine, RP 54476, RP-54476, DALFOPRISTIN

Patent coverage: 2,858 distinct patent families (10,834 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).